Social Support and Health Insurance for Liver Cancer Patients
Part of Cancer, Digestive system clinical trials.
This study looks at how social factors—like health insurance coverage and community support—affect outcomes for people with hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve care and access to treatment for patients who are uninsured or underinsured.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with hepatocellular carcinoma (HCC) at BCLC stage A, B, or C
- You are uninsured or have Medicaid as your primary or secondary insurance
- You are planning to receive active cancer treatment (not just comfort care)
- You are able to understand and sign informed consent forms
- You are not incarcerated or pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
This study looks at why some people with liver cancer are diagnosed at a later stage. Researchers want to understand differences in care and outcomes for patients in certain areas of Los Angeles County.
This trial tests a program to help people with liver cancer get connected to care. It is for patients with specific tumor sizes and numbers, who may face barriers to treatment.
This study aims to improve how patients with liver cancer (hepatocellular carcinoma) get the support and information they need. Researchers will interview patients, caregivers, and healthcare providers to find better ways to navigate care.
This study looks at how social and economic factors (like income, housing, and support) affect people with liver, bile duct, or gallbladder cancer. The goal is to learn more about these factors to improve care and outcomes.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.